Benzinga | Jul 12, 2021 06:50AM EDT

Mizuho Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $134

Mizuho analyst Vamil Divan maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy and raises the price target from $92 to $134.